The importance of donating blood to help others
WACO, Texas (FOX 44) – We at FOX 44 are teaming up with Carter BloodCare to host a Blood Drive this Friday, June 13th!
With this, we would like to provide you with some additional information on the importance of donating.
Carter BloodCare consultant Jessica Amara is here to share more. You can watch our interview in the video above.
While no appointment is necessary for our Blood Drive, you can schedule an appointment online here. You can also scan the QR code below to sign up.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Oscar Health, Inc. (OSCR) Laps the Stock Market: Here's Why
Oscar Health, Inc. (OSCR) closed at $14.34 in the latest trading session, marking a +1.34% move from the prior day. This change outpaced the S&P 500's 0.38% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.24%. Shares of the company witnessed a loss of 14.45% over the previous month, trailing the performance of the Finance sector with its gain of 2.88%, and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of Oscar Health, Inc. in its upcoming release. The company's upcoming EPS is projected at $0.34, signifying a 70.00% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $2.86 billion, reflecting a 28.96% rise from the equivalent quarter last year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.61 per share and a revenue of $11.21 billion, representing changes of +510% and +22.12%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Oscar Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 11.11% decrease. Oscar Health, Inc. is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Oscar Health, Inc. has a Forward P/E ratio of 23.07 right now. This expresses a premium compared to the average Forward P/E of 9.92 of its industry. The Insurance - Multi line industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 92, placing it within the top 38% of over 250 industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oscar Health, Inc. (OSCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Colorado man defies the odds after receiving record blood donation
DENVER (KDVR) — It's the gift of life that saved the life of a Colorado man following a bad crash last year. Ahead of World Blood Donor Day this Saturday, FOX31 spoke to a former patient who defied the odds and is now thanking hundreds of blood donors after he received a record blood donation. FOX31 Newsletters: Sign up to get breaking news sent to your inbox 'I learned that your life can be gone in an instant,' said Nicholas Jackson. 'I hit a nasty patch of road and gravel and I lost control of the motorcycle I was on.' Jackson says that the crash was a defining moment in his life, on June 15, 2024, along Highway 105 near Castle Rock. 'I was launched into a field – and I had to be found,' Jackson recounted. 'My injuries, oh man, they were out of this world.' Jackson suffered a traumatic brain injury, two broken femurs, spine and neck injuries, broken hands and trauma to his abdomen in the crash. 'He was really touch and go,' described Dr. Kaysie Banton of HCA Health One Swedish Hospital, who led his care team after he was airlifted to the hospital's ICU, where he stayed for 48 days. 'His injury severity score would put him in the probably not salvageable, not survivable – grave condition,' Banton said. Arvada organizers join national 'No Kings' protest movement ahead of Saturday rally Despite the grim outlook, Jackson did survive, thanks to more than 500 life-saving blood donations that amounted to 274 units of blood. 'We had to drain our own blood supply, borrowing from six different hospitals, borrowing from two different blood banks … but you can see what we've done with that,' Banton said. The donations gave Jackson a second chance at life and a chance to help others who need life-saving blood. 'Life savers—that's exactly what they are,' Jackson said. 'I am just so thankful for everybody involved, who has ever done that, who has ever contributed or donated- I am so thankful for each and every one of them … it's because of them, I'm still living.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
The European Commission Approves Alnylam's AMVUTTRA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the 13 Biotech Stocks with Huge Upside Potential. It declared on June 9, 2025, that AMVUTTRA® (vutrisiran) has been approved by the European Commission to treat wild-type or hereditary ATTR amyloidosis with cardiomyopathy (ATTR-CM). A researcher studying genetic medicines under a microscope in a biopharmaceutical laboratory. As a result, AMVUTTRA is the first and only RNAi treatment approved in the EU for transthyretin amyloidosis symptoms that show as cardiomyopathy and polyneuropathy. The HELIOS-B Phase 3 research, which revealed a 36% mortality reduction over 42 months and a 28% decrease in all-cause mortality and recurrent cardiovascular events, served as the basis for the approval. More than 6,000 patient-years of safety data support the quarterly administration of the medication. The drug is already authorized in Brazil and the United States. Up to 100,000 individuals in Europe have ATTR amyloidosis, mostly as cardiomyopathy. An RNAi treatment called vutrisiran provides continuous knockdown by stopping TTR production at its source with quarterly injections. Functional and quality-of-life gains were validated by the HELIOS-B trial, which involved patients on SGLT2 inhibitors and tafamidis. Elevations of liver enzymes and injection site responses are frequent adverse effects. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is an innovator in the investigation of RNA interference medicines. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
